Supporting Patients With Opioid Use Disorder

The Medication Assisted Treatment (MAT) Guide  outlines a comprehensive approach to treating and supporting individuals with Opioid Use Disorder (OUD), including how to choose the most appropriate medication, best practices for implementing a MAT program, and how to treat special populations such as pregnant women, youth and individuals involved in the criminal justice system.

MAT is an evidence-based approach to treating OUDs with one of three medications approved by the U.S. Food and Drug Administration: buprenorphine, methadone and naltrexone. This guide focuses on understanding how to use buprenorphine and naltrexone in office-based settings in conjunction with behavioral health treatment and supports. There is also a brief guide for emergency physicians, Alaska Emergency Department Buprenorphine Guide, outlining the key steps to consider when a patient presents to the emergency department with evidence of OUD. This brief guide is intended to be an aid and not an exhaustive manual of all available management options. Another companion guide, Alaska Patient Guide for Beginning Buprenorphine Treatment, was developed specifically for patients.

Learn more: DHSS Press Release, 12/20/19: DHSS releases Medication Assisted Treatment Guide to assist providers in implementing opioid treatment services

 

From Chief Medical Officer Dr. Anne Zink, MD, FACEP

Medication Assisted Treatment Guide

EVALI Update

Healthy Alaskans

Infectious Disease Updates

Medicaid Updates

Behavioral Health Updates

Explaining the Regulatory Process

Response Resources: Support Opioid/Substance Use Disorder

Podcasts, Books, Journal Articles and Resources

DHSS Highlight: Chronic Disease Prevention and Health Promotion Webinars

DHSS Online Public Notices

Upcoming Conferences, Webinars, Trainings and Events

Recent DHSS News and Publications


 

State of Alaska
Department of Health and Social Services
Website: http://dhss.alaska.gov/
Subscribe to this Newsletter.

> Be a fan on Facebook
> Follow us on Twitter